- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:40 | Cathie Wood Effekt beflügelt Biotech: Startet jetzt die Mega-Rallye bei dieser klinischen Wachstumsperle? | Small- & Micro Cap Investment | |||
| Mo | Alamar Biosciences, Inc.: Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases | 305 | GlobeNewswire (Europe) | National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq Neuro 220 panel.
Resulting... ► Artikel lesen | |
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Fr | Alamar's platform to feature in 140+ presentations at AAIC | 1 | Investing.com | ||
| Fr | Über 140 Präsentationen: Alamar-Plattform im Fokus der internationalen Alzheimer-Konferenz | 1 | Investing.com Deutsch | ||
| Fr | Alamar Biosciences, Inc.: Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling | 547 | GlobeNewswire (Europe) | Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and stagingFREMONT, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences... ► Artikel lesen | |
| 07.07. | Alamar launches blood test for Alzheimer's tau tangles | 4 | Investing.com | ||
| 07.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research | 461 | GlobeNewswire (Europe) | eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease
Immunoassay... ► Artikel lesen | |
| 09.06. | Stifel reiterates Buy rating on Alamar Biosciences stock at $28 | 1 | Investing.com | ||
| 02.06. | Alamar Biosciences, Inc.: Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics | 469 | GlobeNewswire (Europe) | NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices
Workflow extends NULISA into longitudinal... ► Artikel lesen | |
| 12.05. | TD Cowen initiates Alamar Biosciences stock with buy rating | 12 | Investing.com | ||
| 12.05. | JPMorgan initiates Alamar Biosciences stock with overweight rating | 1 | Investing.com | ||
| 12.05. | Stifel initiates Alamar Biosciences stock with buy rating | 2 | Investing.com | ||
| 08.05. | Alamar Biosciences, Inc. GAAP EPS of -$1.74, revenue of $26M | 1 | Seeking Alpha | ||
| 08.05. | Alamar Biosciences, Inc.: Alamar Biosciences Reports First Quarter 2026 Financial Results | 435 | GlobeNewswire (Europe) | FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported... ► Artikel lesen | |
| 08.05. | Alamar Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Alamar Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Cathie Wood Is Buying Up Alamar Biosciences Stock After Its IPO. Should You Snag Proteomics-Focused ALMR Too? | 17 | Barchart.com | ||
| 21.04. | Alamar lists on Nasdaq, giving Qiming its fifth IPO in 2026 | 2 | KrASIA | ||
| 20.04. | Alamar Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 20.04. | Alamar Biosciences, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 23,640 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 41,270 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| EVOTEC | 3,468 | -29,83 % | Evotec-Aktie: Geht die Seitwärtsbewegung weiter? | Die Evotec-Aktie bewegt sich seit mehreren Wochen in einer engen Handelsspanne um die Marke von 5 €. Weder den Bullen noch den Bären ist bislang ein nachhaltiger Ausbruch gelungen. Am Mittwoch notiert... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,55 | +0,14 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,34 | -0,07 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| BEAM THERAPEUTICS | 30,990 | -0,03 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| TANGO THERAPEUTICS | 28,350 | -0,04 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,480 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,505 | +0,01 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,79 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CG ONCOLOGY | 72,55 | +0,07 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,515 | -0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,295 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,300 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TARSUS PHARMACEUTICALS | 59,28 | -0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen |
Das Unternehmen ALAMAR BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,07 % bei einem Aktienkurs von 27,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.